(Q38566193)

English

Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort

scientific article published on 14 August 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

14

object named as

Julien Taieb

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

11

object named as

Romain Coriat

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

author name string

Daniel Pietrasz

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Lysiane Marthey

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Mathilde Wagner

3

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Jean-Frédéric Blanc

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Christophe Laurent

5

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Olivier Turrini

6

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Jean Luc Raoul

7

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Eric Terrebonne

8

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Olivia Hentic

9

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Isabelle Trouilloud

10

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Nicolas Regenet

12

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Pasquale Innominato

13

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Antonio Sa Cunha

15

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Jean Baptiste Bachet

16

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

publication date

14 August 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Annals of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

22 Suppl 3

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

S1196-205

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

New challenges in perioperative management of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Management of borderline resectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

'Artery-first' approaches to pancreatoduodenectomy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Postoperative pancreatic fistula: an international study group (ISGPF) definition.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Utility of tumor markers in determining resectability of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

One thousand consecutive pancreaticoduodenectomies

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4783-X

21 January 2018

Identifiers

10.1245/S10434-015-4783-X

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38566193&oldid=2201834967"